Lotus Pharmaceutical Co., Ltd., and Orion Corp., have entered into an exclusive marketing and distribution agreement on two branded products indicated for the treatment of parkinsonâs disease, Stalevo and Comtan, in the Asia Pacific region. The agreement provides full sales and marketing control over the brands in basically every major Asian market including Taiwan, Korea, Hong Kong, Philippines, Vietnam, Indonesia and Bangladesh. Upon transferring the MA, the transaction is expected to be closed in the third quarter of 2020.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
280.5 TWD | -0.71% | -2.09% | +3.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.12% | 2.32B | |
+38.59% | 727B | |
-7.89% | 354B | |
+15.66% | 328B | |
+0.24% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+4.23% | 164B | |
-1.70% | 164B |
- Stock Market
- Equities
- 1795 Stock
- News Lotus Pharmaceutical Co., Ltd.
- Lotus Pharma and Orion to Enter into Marketing and Distribution Agreement